Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Apr 22, 2023 10:27pm
179 Views
Post# 35409116

RE:worth a read...only a month old , recent enough

RE:worth a read...only a month old , recent enough
great report with a lot of caveats so hope it all goes well and am sure the process is very painstaking.
As for price targets, they don't mean a lot and even the anlaysts have difficulty with their evaluations.
I just wish that RBC had not downgraded onc from thier original 9 dollars to their now 6 dollars as this does not instill a lot of confidence going forward especially at this stage of the game.
As stated all should be very clear or at least a very clear signal once bracelet results are released. If there is any hesitation or delays or now we only need to do this or wait for os or something else from onc then that would be considered a problem IMO only. Of course we are a very forgiving and understanding group but any further delays would have to be explained a lot better than what onc has been forthcoming to shareholders with and again IMO.
<< Previous
Bullboard Posts
Next >>